[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 226
1. Verma S, Younus J, Haynes AE, Stys-Norman D, Blackstein M, Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline. Curr Oncol; 2008 Apr;15(2):80-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline.
  • QUESTIONS: In patients with inoperable locally advanced or metastatic soft tissue sarcoma, does first-line dose-intensive chemotherapy supported by growth factor or autologous bone marrow or stem-cell transplantation improve response rate, time to disease progression, or survival as compared with standard-dose chemotherapy?
  • PERSPECTIVES: Because therapeutic options for adult patients with advanced or metastatic soft tissue sarcoma are scarce and the possibility of cure for these patients is extremely limited, the Sarcoma Disease Site Group (dsg) felt that a review of the available literature on dose-intensive chemotherapy for adult patients with locally advanced or metastatic soft tissue sarcoma and subsequent development of a clinical practice guideline based on the evidence were important.
  • The practice guideline report was reviewed and approved by the Sarcoma dsg, which comprises medical oncologists, radiation oncologists, surgeons, a pathologist, a methodologist, and community representatives.
  • PRACTICE GUIDELINE: Based on the systematic review, consensus, and external review, the Sarcoma dsg makes these recommendations: Dose-intensive chemotherapy with growth factor support is not recommended in the first-line treatment of patients with inoperable locally advanced or metastatic soft tissue sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Feb 15;77(4):675-82 [8616759.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S194-8 [8453697.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1551-8 [9389914.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):871-6 [9789610.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):917-9 [9789617.001]
  • [Cites] Am J Clin Oncol. 1999 Jun;22(3):267-72 [10362334.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2676-84 [10894866.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1498-506 [15042685.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):105-12 [15625365.001]
  • [Cites] Cancer Treat Rep. 1985 May;69(5):499-504 [3924401.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S180-4 [8453694.001]
  • [Cites] Am J Clin Oncol. 1996 Feb;19(1):78-81 [8554042.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1221-7 [9317171.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1438-43 [9552049.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):66-72 [10211090.001]
  • [Cites] Tumori. 1999 Jul-Aug;85(4):229-33 [10587022.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):161-6 [11863099.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2629-36 [7595717.001]
  • [Cites] J Surg Oncol. 1995 Jun;59(2):110-5 [7776651.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1418-26 [9193334.001]
  • (PMID = 18454188.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2365487
  • [Keywords] NOTNLM ; Soft tissue sarcoma / autologous bone marrow or stem-cell transplantation / clinical practice guideline / dose-intensive chemotherapy / growth factor
  •  go-up   go-down


2. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M, Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer; 2008 Mar 15;112(6):1197-205
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review.
  • A systematic review was performed to determine whether first-line dose-intensive chemotherapy supported by growth factor or autologous bone marrow/stem cell transplantation improves response rate, time-to-disease progression, or survival compared with standard-dose chemotherapy in patients with inoperable, locally advanced, or metastatic soft tissue sarcoma.
  • On the basis of the available evidence, high-dose chemotherapy with growth factor or autologous bone marrow/stem cell transplantation should not be used in the routine treatment of patients with inoperable, locally advanced, or metastatic soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Growth Substances / administration & dosage. Sarcoma / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18224666.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances
  • [Number-of-references] 35
  •  go-up   go-down


3. Jain A, Sajeevan KV, Babu KG, Lakshmaiah KC: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer; 2009 Oct-Dec;46(4):274-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in adult soft tissue sarcoma.
  • Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms.
  • Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma.
  • We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma.
  • In locally advanced and metastatic STSs, single agent adriamycin remains the basic standard of medication.
  • Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoadjuvant Therapy


Advertisement
4. Hartmann JT: Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs; 2007 Mar;18(3):245-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
  • Small round cell sarcoma, such as Ewing/PNET, desmoplastic small round cell sarcoma and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensitive and neoadjuvant protocols regardless of size or overt metastatic disease.
  • A limited number of effective agents available for the treatment of patients with metastatic adult soft-tissue sarcoma exists, which have failed anthracyline and ifosfamide-based chemotherapy.
  • Most other high-grade (grading >I) so-called adult-type soft-tissue sarcomas such as fibro, lipo, pleomorphic and synovial sarcoma are treated with a anthracycline-based regimen with or without ifosfamide as front-line therapy.
  • In this review, the therapeutic activities of drugs currently available as second-line treatment in patients with metastatic soft tissue sarcoma are summarized, providing an overview of contentious or emerging treatment issues.
  • In relapsed 'adult-type' soft-tissue sarcomas trofosfamide, gemcitabine and ecteinascidin (ET-743) appear to be drugs associated with moderate activity and an acceptable toxicity profile.
  • An interesting finding to be noted is that the different drugs have particular effects in distinct subtypes of soft-tissue sarcoma; however, it has to be taken into account that the number of patients included in those phase II trials are limited.
  • The so-called selective therapy targeting vascular endothelial growth factor (receptor), epidermal growth factor receptor, c-kit, Raf kinase or platelet-derived growth factor receptor and bcl-2 antisensing, proteasome, protein kinase C/B, and mammalian target of rabamycin inhibition will continue to be tested in gastrointestinal stromal tumors patients refractory to imatinib mesylate as well as in selected sarcoma subtypes.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264755.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anthracyclines; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Taxoids; 0 / Topoisomerase I Inhibitors; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 91
  •  go-up   go-down


5. Chui CH: Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS). Surg Oncol; 2007 Nov;16(3):187-93
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS).
  • Nonrhabdmyosarcoma soft tissue sarcoma (NRSTS) is a heterogenous group of tumors analyzed as a unique group because of the rarity of each histopathological subtype.
  • Initial information available has been obtained from adult series or pediatric case studies.
  • Identification of sarcoma-specific chromosomal translocations has allowed for more accurate definitive diagnosis.
  • Prognosis in patients with metastatic disease has been poor despite combination chemotherapy with surgical resection.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707639.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 42
  •  go-up   go-down


6. Hartmann JT, Patel S: Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs; 2005;65(2):167-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
  • The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.
  • Small round cell tumours (SRCTs), such as Ewing's sarcoma/primitive neuroectodermal tumour, desmoplastic SRCT and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies, which are treated with multimodality, dose-intensive, neoadjuvant protocols regardless of size or overt metastatic disease.
  • Most other high-grade (grading >I), so-called 'adult type', soft tissue sarcomas such as fibrosarcoma, liposarcoma, pleomorphic and synovial sarcomas are treated with an anthracycline-based regimen with or without ifosfamide as front-line therapy.
  • In relapsed 'adult type' soft tissue sarcomas, trofosfamide, gemcitabine and trabectedin (ecteinascidin 743) appear to be drugs associated with some activity and an acceptable toxicity profile.
  • A high activity has been reported for the taxanes, in particular for paclitaxel, in vascular sarcomas located in the scalp or face and in Kaposi's sarcoma.
  • It is interesting to note that the different drugs have particular effects in distinct subtypes of soft tissue sarcoma; however, it should be taken into account that the number of patients included in the phase II trials is limited.
  • Targeted therapy inhibiting vascular endothelial growth factor receptor, epidermal growth factor receptor, RAF kinase, c-KIT or platelet-derived growth factor receptors will continue to be tested in GIST patients refractory to imatinib and in other sarcoma histologies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Metastasis / drug therapy. Salvage Therapy. Sarcoma / drug therapy. Sarcoma / pathology


7. Sleijfer S, Seynaeve C, Verweij J: Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist; 2005 Nov-Dec;10(10):833-41
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.
  • The group of soft tissue sarcomas in adult patients is a heterogeneous group with more than 40 different subtypes.
  • While local treatment remains the mainstay for localized disease, systemic chemotherapy can importantly contribute in the treatment of advanced soft tissue sarcoma.
  • For patients with metastatic disease, chemotherapy is a palliative treatment in the vast majority of the cases.
  • This review addresses the current available data on chemotherapy for adult patients with soft tissue sarcoma, excluding gastrointestinal stromal tumor, the Ewing-like sarcomas, and other small blue round cell tumors.
  • In addition, it is increasingly recognized that future research in soft tissue sarcoma should focus on the identification of tumor factors that can serve as targets for treatment and that the diverse tumor subtypes should be analyzed separately for their sensitivity to systemic treatment.
  • [MeSH-major] Sarcoma / drug therapy
  • [MeSH-minor] Adult. Anthracyclines / administration & dosage. Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314294.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  • [Number-of-references] 50
  •  go-up   go-down


8. Canter RJ, Qin LX, Downey RJ, Brennan MF, Singer S, Maki RG: Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis. Cancer; 2007 Nov 1;110(9):2050-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis.
  • BACKGROUND: The benefit of chemotherapy in the treatment of primary soft-tissue sarcoma (STS) is controversial.
  • To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity.
  • CONCLUSIONS: Although it is difficult to completely control for the effects of selection bias on outcome in this highly selected cohort of patients, data from the current study suggest that systemic chemotherapy has minimal, if any, long-term impact on the outcome of patients undergoing pulmonary resection for metastatic STS of the extremity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Extremities / pathology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Sarcoma / secondary. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Perioperative Care. Pulmonary Surgical Procedures. Retrospective Studies. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / therapy


9. Vincenzi B, Frezza AM, Santini D, Tonini G: New therapies in soft tissue sarcoma. Expert Opin Emerg Drugs; 2010 Jun;15(2):237-48
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapies in soft tissue sarcoma.
  • IMPORTANCE OF THE FIELD: Soft tissue sarcomas are rare mesenchymal tumors accounting for < 1% of all adult neoplasia.
  • In the last decade, locally advanced and metastatic soft tissue sarcoma have been managed only through surgery, radiotherapy and standard chemotherapy (mainly based on anthracycline and ifosfamide).
  • Despite the efforts, overall 5-year survival rate in patients with soft tissue sarcomas of all stages remains only 50 - 60%.
  • AREAS COVERED IN THIS REVIEW: In the present article, all the main new molecules under clinical evaluation for the treatment of soft tissue sarcoma are revised by describing the mechanism of action, the biological rationale of their use in sarcoma and by reporting the available data about safety and efficacy, up to 2009.
  • WHAT THE READER WILL GAIN: A brief summary of the standard treatments available at the moment and a complete analysis of the state of art about the development of new target therapies in the management of soft tissue sarcoma.
  • TAKE HOME MESSAGE: The identification of new biological therapies that target soft tissue sarcoma tumorigenesis key points seems to offer a real opportunity of improving the prognosis of this often aggressive disease.
  • In this sense, the best management for soft tissue sarcoma patients is in a clinical trial and participation in clinical trials should be encouraged.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drugs, Investigational / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20465449.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 77
  •  go-up   go-down


10. Hartmann JT, Patel S: New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep; 2005 Jul;7(4):300-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New drug developments for patients with metastatic soft tissue sarcoma.
  • Small round cell sarcomas (SRCT), such as Ewing/primitive neuroectodermal tumor, desmoplastic SRCT, and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies that are treated with multimodality dose-intensive neoadjuvant protocols regardless of size or overt metastatic disease.
  • However, the number of effective cytotoxic agents for the treatment of patients with metastatic so-called adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Curr Oncol Rep. 2012 Apr;14(2):220 [22371000.001]
  • (PMID = 15946590.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


11. Daigeler A, Lehnhardt M, Sebastian A, Belyaev O, Steinstraesser L, Steinau HU, Kuhnen C: Metachronous bilateral soft tissue sarcoma of the extremities. Langenbecks Arch Surg; 2008 Mar;393(2):207-12
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous bilateral soft tissue sarcoma of the extremities.
  • BACKGROUND AND AIMS: Synchronous and heterochronous multiple soft tissue sarcoma of the extremities is very rare.
  • Out of 1,201 of our patients, 4 patients presented with symmetrical bilateral soft tissue sarcoma of the extremities.
  • RESULTS: All tumours were located at the extremities and were diagnosed as leiomyosarcoma in two patients, malignant fibrous histiocytoma and clear cell sarcoma in one patient each.
  • In two patients a second primary sarcoma of the same entity was considered the most likely diagnosis, whereas in one patient a contralateral lymph node metastasis and in one other patient an atypical soft tissue metastasis had to be taken into account.
  • Aside from irradiation effects, exposition to other carcinogenic agents or genetic predisposition, the reasons for the clustering of soft tissue sarcoma in one same patient remain still unclear.
  • Only one patient, although suffering from disseminated metastatic disease was living at follow-up time, the other three patients had already died.
  • CONCLUSION: The interpretation of the bilateral manifestation of soft tissue sarcoma remains open, but predicts an unfavourable outcome.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242894.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Yildirim H, Metintaş M, Ak G, Dündar E, Erginel S: Soft tissue sarcoma metastatic to pleura. Tuberk Toraks; 2008;56(2):197-200
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma metastatic to pleura.
  • However, pleural metastases of soft tissue sarcoma that constitute less than 1% of adult solid malignancy are extremely rare.
  • We report a 57 year-old man who presented to us with left chest pain and progressive dyspnea and was diagnosed to have a pleural metastases of soft tissue sarcoma by thoracoscopic biopsy.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Sarcoma / pathology. Thoracoscopy / methods

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Tuberk Toraks. 2008;56(4):487-8; author reply 488 [19123090.001]
  • [CommentIn] Tuberk Toraks. 2008;56(4):485; author reply 486 [19123089.001]
  • (PMID = 18701980.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


13. Italiano A, Delva F, Brouste V, Terrier P, Trassard M, Michels J, Collin F, Coindre J, Blay J, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database. J Clin Oncol; 2009 May 20;27(15_suppl):10504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database.
  • : 10504 Background: The SMAC meta-analysis failed to demonstrate that adjuvant chemotherapy (AC) significantly improves overall survival (OS) in adult patients with localised resectable soft-tissue sarcoma (STS).
  • We report here the analysis of the impact of AC in the population of STS patients included in the prospective database of the French Sarcoma Group.
  • 152 pts were excluded from the study because of metastatic disease at diagnosis.
  • The commonest pathological subtypes were MFH 22.5%, liposarcoma 18%, leiomyosarcoma 13%, and synovial sarcoma 10%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Pink D, Rahm J, Schoeler D, Schoenknecht TM, Reichardt P: Activity of paclitaxel in radiation induced and other secondary angiosarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):10578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10578 Background: Angiosarcomas (AS) represent 1-2% of adult soft tissue sarcomas and can arise anywhere in the body.
  • 3 pts. were diagnosed with locally advanced/metastatic SAS.
  • All 14 patients with recurrent/metastatic disease were treated with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Farshadpour F, Schaapveld M, Suurmeijer AJ, Wymenga AN, Otter R, Hoekstra HJ: Soft tissue sarcoma: why not treated? Crit Rev Oncol Hematol; 2005 Apr;54(1):77-83
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma: why not treated?
  • BACKGROUND: Soft tissue sarcomas (STS) are uncommon malignancies and elderly STS patients have been reported to receive less definitive treatment compared to young STS patients.
  • RESULTS: From 1989 to 1999, 620 patients (including 56 Kaposi sarcoma) were registered with primary STS.
  • The reasons for no treatment were irresectability of the sarcoma (65%), metastatic disease (11%), comorbidity (4%), poor general health (5%), death prior to therapy (7%) and refusal of therapy (3%) (motivation not documented in 5%).
  • Withholding treatment was mostly disease-related (76%), e.g. irresectable retroperitoneal STS or metastatic disease; for 19% of the patients, it was related to their poor general health.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Health Status. Humans. Male. Middle Aged. Motivation. Neoplasm Staging. Netherlands. Prognosis. Retrospective Studies. Withholding Treatment

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780909.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


16. Kopp HG, Patel S, Brücher B, Hartmann JT: Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am J Clin Dermatol; 2008;9(4):207-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
  • Soft-tissue sarcomas (STS) include a spectrum of histologically and clinically different tumors.
  • We summarize current treatment options for metastatic STS, including established first-line chemotherapy approaches, mainly with anthracyclines and/or ifosfamide and second-line treatment choices beyond anthracyclines.
  • Until only a few years ago, treatment choices for metastatic STS were easy to review because of the very limited number of active compounds available.
  • In order to be successful, it may be necessary to combine not only different compounds but also different targets beyond the proliferation machinery of sarcoma cells such as tumor angiogenesis, the tumor stromal compartment, or tumor cell oncogene products.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / administration & dosage. Anthracyclines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Humans. Neoplasm Staging. Protein Kinase Inhibitors / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18572972.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 108
  •  go-up   go-down


17. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, Duggal A, Steadman P: Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg; 2006 Mar;76(3):104-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical margin and its influence on survival in soft tissue sarcoma.
  • BACKGROUND: The goal of surgeons treating soft tissue sarcoma is to gain local control, to avoid risk of local recurrence and to avoid compromise of the patient's potential survival.
  • METHODS: Two hundred and seventy-nine patients who presented with soft tissue sarcoma without metastatic disease were analysed.
  • RESULTS: The extent of the surgical margin was not clinically or statistically significant in the development of metastatic disease.
  • [MeSH-major] Sarcoma / mortality. Sarcoma / surgery. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2006 Mar;76(3):97 [16626338.001]
  • (PMID = 16626341.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


18. Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza S, Wassermann B, Picci P, Perris R: NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res; 2009 Jan;27(1):135-40
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients.
  • Enhanced expression levels of NG2 proteoglycan in presurgical original lesions of soft-tissue sarcoma (STS) patients defines with 55% probability the immediate (i.e., within 12 months postsurgery) risk in these individuals to develop postsurgical secondary lesions, independently of any other clinical trait.
  • Evaluation of the timing of metastasis formation in patients with high and low levels of NG2 in their primitive lesions further stratified the patients in subsets with diverse lag phases in the occurrence of metastatic disease.
  • In our cohort of high-grade STS cases, transcription of NG2 also showed a 81-fold amplification in metastatic lesions, when compared to primitive ones, and this gene overexpression was accompanied by an abundant but nonuniform in situ expression of its product.
  • In a similar manner as seen in primitive lesions, patients with higher levels of metastatic NG2 encountered a significantly more dismal clinical course.
  • Therefore, minimally invasive assessment of the transcription levels of the NG2 gene represents a parameter capable of predicting the arising of metastatic disease within a definite postsurgery time interval, and affords in adjunct in the definition of life expectance in STS patients.
  • [MeSH-major] Antigens / biosynthesis. Gene Expression Regulation, Neoplastic. Proteoglycans / biosynthesis. Sarcoma / metabolism. Sarcoma / pathology. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Prognosis. Transcription, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634019.001).
  • [ISSN] 1554-527X
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  •  go-up   go-down


19. Kasper B, Gil T, Awada A: Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol; 2007 Jul;19(4):336-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?
  • PURPOSE OF REVIEW: We give an overview on the emerging compounds for patients with soft tissue sarcoma.
  • RECENT FINDINGS: Soft tissue sarcomas are a heterogeneous group of tumours that arise predominantly from the embryonic mesoderm.
  • They account for fewer than 1% of all adult malignancies.
  • The prognosis of patients with advanced metastatic soft tissue sarcoma remains poor, with disease-free survival at 5 years below 10%.
  • SUMMARY: Understanding of the molecular biology and pathogenesis of soft tissue sarcomas has been enhanced, and in the near future this should translate into molecular tumour characterization and development of new therapeutic strategies.
  • [MeSH-major] Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545796.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Receptors, Growth Factor; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 32
  •  go-up   go-down


20. Smith R, Pak Y, Kraybill W, Kane JM 3rd: Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. Eur J Surg Oncol; 2009 Apr;35(4):356-61
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy.
  • AIMS: To identify clinicopathologic and treatment variables associated with long-term overall survival (OS) in soft tissue sarcoma (STS) patients with lung metastases undergoing pulmonary metastasectomy (PM).
  • Eighteen patients had synchronous metastatic disease.
  • [MeSH-major] Lung Neoplasms / secondary. Retroperitoneal Neoplasms / mortality. Sarcoma / mortality. Sarcoma / secondary. Uterine Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Extremities / surgery. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294807.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Hui AC, Ngan SY, Wong K, Powell G, Choong PF: Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience. Eur J Surg Oncol; 2006 Dec;32(10):1159-64
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience.
  • AIM: Radiotherapy has been shown to improve local control in combination with limb-sparing or conservative surgery in the management of localised soft tissue sarcoma.
  • METHODS: Consecutive patients with localised extremity or truncal soft tissue sarcoma who presented between January 1996 and December 2000 and treated with preoperative radiotherapy followed by limb-sparing surgery were reviewed.
  • Patients with recurrent disease or metastatic disease at diagnosis and patients below the age of 16years were excluded.
  • CONCLUSION: Preoperative radiotherapy followed by surgery provides effective local control in the management of soft tissue sarcoma.
  • [MeSH-major] Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Radiation Injuries. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765559.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Iwata T, Nishiyama N, Izumi N, Tsukioka T, Suehiro S: Metastatic monophasic synovial sarcoma of the pleura. Ann Thorac Cardiovasc Surg; 2007 Aug;13(4):258-61
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic monophasic synovial sarcoma of the pleura.
  • Pleural metastasis of synovial sarcoma that originally developed in the soft tissue is a very rare entity.
  • An asymptomatic 25-year-old female, with a history of a resected synovial sarcoma in her left brachial muscle and pulmonary metastasectomy of the right lung, presented a small nodule in the periphery of the left lung on a routine chest-computed tomography.
  • A soft flat red tumor approximately 2 cm in diameter was shown on the pleura of the lingula, mimicking a blood clot on the pleura.
  • Intraoperative frozen sectioning evidenced metastatic synovial sarcoma.
  • We diagnosed unresectable pleural metastases of synovial sarcoma and finished the operation after sampling another pulmonary pleural lesion.
  • Postoperative histopathological examination revealed a solid and bundle-like proliferation of a short spindle cell tumor with a monophasic pattern, which was diagnosed as a metastatic pleural synovial sarcoma.
  • [MeSH-major] Muscle Neoplasms / pathology. Pleural Neoplasms / secondary. Sarcoma, Synovial / secondary
  • [MeSH-minor] Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717503.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miyagi T, Maeda Y, Kitagawa Y, Kadono Y, Konaka H, Namiki M: Role of surgical resection in adult urological soft tissue sarcoma: 25-year experience. Urol Int; 2010;84(3):309-14
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of surgical resection in adult urological soft tissue sarcoma: 25-year experience.
  • INTRODUCTION: As adult urological soft tissue sarcomas (STS) are rare, there have been few recent large-scale studies of these tumors.
  • This report describes a single institutional experience of adult urological STS over 25 years.
  • PATIENTS AND METHODS: The study population consisted of 25 adult patients with histologically diagnosed STS arising in the urinary tract, male genital system, or retroperitoneum between January 1983 and July 2008.
  • CONCLUSIONS: Surgical resection, regardless of status of surgical resection margin, contributed to a favorable prognosis in adult patients with locally advanced or metastatic urological STS.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Urologic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20389161.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Abraham JA, Baldini EH, Butrynski JE: Management of adult soft-tissue sarcoma of the extremities and trunk. Expert Rev Anticancer Ther; 2010 Feb;10(2):233-48
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adult soft-tissue sarcoma of the extremities and trunk.
  • Soft-tissue sarcomas are a heterogeneous group of tumors consisting of approximately 100 distinct diagnoses.
  • Treatment of metastatic disease continues to be difficult, but current research focuses on clarifying molecular mechanisms of disease and identifying new potential targets for medical therapy.
  • [MeSH-major] Sarcoma / surgery
  • [MeSH-minor] Adult. Extremities. Humans. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131999.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Krempien R, Roeder F, Oertel S, Weitz J, Hensley FW, Timke C, Funk A, Lindel K, Harms W, Buchler MW, Debus J, Treiber M: Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):773-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma.
  • PURPOSE: This study assesses the long-term outcome of patients with retroperitoneal soft-tissue sarcomas treated by maximal resection in combination with intraoperative electron-beam therapy (IOERT) and postoperative external-beam radiotherapy.
  • METHODS AND MATERIALS: From 1991 to 2004, 67 patients were treated with curative intent for primary (n = 26) or recurrent (n = 41) retroperitoneal soft-tissue sarcoma.
  • RESULTS: The 5-year actuarial overall survival (OS), disease-free survival, local control (LC), and freedom from metastatic disease of all patients was 64%, 28%, 40%, and 50%, respectively.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Intraoperative Period. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682152.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Nugent SL, Dim DC, Bridge JA, Ioffe OB: Clear cell sarcoma of soft tissue metastatic to the ovaries: a heretofore unreported occurrence. Int J Gynecol Pathol; 2009 May;28(3):234-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma of soft tissue metastatic to the ovaries: a heretofore unreported occurrence.
  • Clear cell sarcoma of soft tissue (CCSST) is a rare soft tissue neoplasm with marked variable tumor progression and prognosis.
  • Her past medical history was significant for clear cell sarcoma of the left foot 2 years earlier.
  • To the best of our knowledge, this is the first reported case of CCSST metastatic to the ovaries.
  • [MeSH-major] Ovarian Neoplasms / secondary. Sarcoma, Clear Cell / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Calmodulin-Binding Proteins / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ovariectomy. RNA-Binding Proteins / genetics

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620941.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calmodulin-Binding Proteins; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


27. Bauer S, Hartmann JT: Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors. Crit Rev Oncol Hematol; 2006 Nov;60(2):112-30
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors.
  • However, for patients with locally advanced or metastatic disease chemotherapeutic treatments have not greatly changed the poor outcome of the disease.
  • For patients with metastatic sarcoma long-term survival can only be achieved in a small number of patients with mostly resectable disease.
  • A variety of new drugs or drug combinations seem to exhibit considerable activity in certain histological sarcoma subtypes, which may soon broaden the armamentarium of drugs for a subset of patients.
  • However, with the vastly improved understanding of the biology and pathology of soft tissue sarcoma an era of opportunities seems to have begun and the recent success in the treatment of gastrointestinal stromal tumors impressively shows how fast a gain in the understanding of oncogenic mechanisms may translate into a highly efficient, clinically useful treatment.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / radiotherapy. Sarcoma / drug therapy. Sarcoma / radiotherapy

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949832.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 138
  •  go-up   go-down


28. Wang ZH, Shi HY, Wang ZB: [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases]. Ai Zheng; 2009 Nov;28(11):1214-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases].
  • BACKGROUND AND OBJECTIVE: Metastatic alveolar soft tissue sarcoma (ASTS) of the central nervous system is rare and is easy to be misdiagnosed as other primary tumors of central nervous system.
  • The metastatic lesions were located in the posterior cranial fossa, closely associated with the meninges.
  • CONCLUSION: ASTS of the central nervous system was mostly metastatic and should be differentiated from other CNS tumors such as meningioma, melonocytic tumor, rhabdomyosarcoma and paraganglioma.
  • Metastatic ASTS of the central nervous system had poor prognosis and the five-year survival rate was low.
  • [MeSH-major] Cranial Fossa, Posterior. Sarcoma, Alveolar Soft Part / pathology. Sarcoma, Alveolar Soft Part / secondary. Skull Base Neoplasms / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Actins / metabolism. Adult. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasm Recurrence, Local. Paraganglioma / diagnosis. Prognosis. Rhabdomyosarcoma / diagnosis. S100 Proteins / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / S100 Proteins
  •  go-up   go-down


29. Bisogno G, Ferrari A, Bergeron C, Scagnellato A, Prete A, Alaggio R, Casanova M, D'Angelo P, Di Cataldo A, Carli M: The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer; 2005 Apr 15;103(8):1719-24
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
  • BACKGROUND: The role of doxorubicin (Doxo) as part of multidrug regimens used to treat children with soft tissue sarcoma (STS) is controversial.
  • To evaluate the feasibility of combining Doxo with the well established ifosfamide, vincristine, and actinomycin D (IVA) regimen, the Italian STS Committee performed a pilot study on a series of children with metastatic STS.
  • This combination will be investigated in high-risk patients with rhabdomyosarcoma in a randomized trial launched by the European pediatric Soft tissue sarcoma Study Group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dactinomycin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Male. Pilot Projects. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15754335.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


30. Jakob J, Wenz F, Dinter DJ, Ströbel P, Hohenberger P: Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2009 Nov 1;75(3):810-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
  • PURPOSE: To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS).
  • PATIENTS AND METHODS: A cohort of 15 consecutive patients with nonmetastasized, primary high-grade or locally recurrent Stage III (n = 14) or IIb (n = 1) STS not amenable to surgical resection without significant organ or extremity function loss was prospectively investigated.
  • Five patients did not undergo surgery because of intercurrent metastatic disease, unresectable disease, or refusal.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Radiotherapy, Intensity-Modulated. Sarcoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Nausea / etiology. Postoperative Complications. Prospective Studies. Radiation Injuries / etiology. Radiotherapy Dosage. Remission Induction. Tumor Burden. Vomiting / etiology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307066.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


31. Fayette J, Penel N, Chevreau C, Blay JY, Cupissol D, Thyss A, Guillemet C, Rios M, Rolland F, Fargeot P, Bay JO, Mathoulin-Pelissier S, Coindre JM, Bui-Nguyen B: Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs; 2009 Oct;27(5):482-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
  • Multidrug chemotherapy increases responses in advanced soft tissues sarcoma.
  • Treatment with intensified MAID did not improve response rate neither survival and cannot be recommended for advanced or metastatic soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leiomyosarcoma / drug therapy. Liposarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Dacarbazine / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148579.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


32. Gupta AA, Pappo AS: New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children. Future Oncol; 2006 Oct;2(5):675-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
  • Children with relapsed, recurrent or metastatic sarcomas represent a therapeutic challenge for the pediatric oncologist.
  • For example, drug development in rhabdomyosarcoma has relied upon the preclinical xenograft model, whereas therapies for pediatric nonrhabdomyosarcomatous soft tissue sarcomas have mostly been derived from adult trials.
  • [MeSH-major] Camptothecin / analogs & derivatives. Drug Design. Sarcoma / drug therapy. Sarcoma / secondary. Topotecan / therapeutic use

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026459.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; 7M7YKX2N15 / Topotecan; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 82
  •  go-up   go-down


33. Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F: Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer; 2008 Jun;50(6):1147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma.
  • BACKGROUND: Recent technical advances in CT imaging and data processing have improved the ability to detect small pulmonary nodules in children with bone and soft-tissue sarcoma undergoing radiologic imaging of the chest.
  • PROCEDURE: We retrospectively studied medical records and CT chest scans at initial diagnosis of 210 children and young adults presenting to a single pediatric tertiary care hospital specialized in oncology for evaluation of bone or soft-tissue sarcoma.
  • Of patients who underwent biopsy or resection of a nodule, 41.7% had metastatic pulmonary disease.
  • Having more than three nodules and a bilateral distribution were associated with histology-proven metastasis (P = 0.002 and P = 0.011, respectively) and an increased frequency of recurrent or progressive metastatic disease in the lung (P < 0.001 and P = 0.023, respectively).
  • CONCLUSIONS: Pulmonary nodules were commonly detected during the initial evaluation of pediatric cases of sarcoma.
  • Number and distribution of nodules were significantly associated with metastatic disease and outcome.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Radiography, Thoracic. Sarcoma / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Solitary Pulmonary Nodule / radiography

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18300316.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol; 2007 Jul 1;25(19):2755-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
  • PURPOSE: Gemcitabine as a single agent and the combination of gemcitabine and docetaxel have activity in patients with metastatic soft tissue sarcoma.
  • To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bayes Theorem. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome


35. Rehders A, Hosch SB, Scheunemann P, Stoecklein NH, Knoefel WT, Peiper M: Benefit of surgical treatment of lung metastasis in soft tissue sarcoma. Arch Surg; 2007 Jan;142(1):70-5; discission 76
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit of surgical treatment of lung metastasis in soft tissue sarcoma.
  • HYPOTHESIS: Patients with pulmonary metastatic soft tissue sarcoma benefit from resection, with long-term cure possible.
  • PATIENTS: Between January 1, 1991, and December 31, 2002, 61 patients (33 men and 28 women; median age at initial diagnosis, 42 years [age range, 18-74 years]) were surgically treated for pulmonary metastases of soft tissue sarcoma at University Hospital, Hamburg-Eppendorf, Germany.
  • The mean number of resected pulmonary metastatic lesions was 5 (range, 1-48).
  • The number of resected lung metastatic lesions had no prognostic relevance (P = .37).
  • CONCLUSIONS: Patients with lung metastasis from soft tissue sarcomas benefit from surgical excision.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Histiocytoma / secondary. Histiocytoma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Sternum / surgery. Survival Analysis. Thoracotomy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224503.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G, Milano A, Apice G: Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res; 2005 Nov-Dec;25(6C):4519-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological prognostic factors in adult soft tissue sarcomas.
  • Adult soft tissue sarcomas (STSs) are a rare group of highly heterogeneous neoplasms arising in different tissues.
  • The most common metastatic sites are lung, lymph nodes, liver, bone and soft tissues.
  • [MeSH-major] Sarcoma / metabolism. Sarcoma / pathology. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / biosynthesis. Humans. Prognosis


37. Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A: Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol; 2006 Feb;29(1):59-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
  • OBJECTIVE: The availability of effective chemotherapy agents or regimens for soft tissue sarcomas (STS) is limited.
  • A multi-institutional study of gemcitabine in patients with STS, without prior chemotherapy for metastatic disease, was initiated in the Southwest Oncology Group May 1, 1998 and completed March 15, 1999.
  • MATERIALS AND METHODS: Patients were required to have metastatic or unresectable STS with no prior chemotherapy for metastatic disease.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462504.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


38. Aranha O, Agulnik M: Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions. Expert Opin Ther Targets; 2008 Feb;12(2):197-207
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions.
  • Given the overwhelming chemotherapy resistance of the disease, patients with progressive and metastatic soft tissue sarcomas are ideal candidates for trials of investigational new drugs.
  • OBJECTIVE: The authors review the molecular mechanisms underlying soft tissue sarcomas and discuss molecularly targeted therapies developed to improve the poor outcome of these uncommon tumors.
  • METHODS: A Medline and American Society of Clinical Oncology abstract search was conducted using the keyword 'soft tissue sarcoma'.
  • Articles and abstracts were reviewed and eligible for inclusion if they used targeted therapies for the treatment of patients with soft tissue sarcomas.
  • RESULTS/CONCLUSION: Phase II clinical trials for patients with soft tissue sarcomas using novel targets and present recognized targets are ongoing and planned.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Drug Delivery Systems / methods. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18208368.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 80
  •  go-up   go-down


39. Schmitt T, Keller E, Dietrich S, Wuchter P, Ho AD, Egerer G: Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis. Mar Drugs; 2010;8(10):2647-58
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
  • Soft tissue sarcoma (STS) comprises a large variety of rare malignant tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / therapeutic use. Sarcoma / drug therapy. Tetrahydroisoquinolines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Disease Progression. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Urochordata. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6780-4 [10841573.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):e198-200 [19805684.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):339-48 [15578712.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):576-84 [15659504.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5484-92 [16110008.001]
  • [Cites] Oncologist. 2005 Nov-Dec;10(10):833-41 [16314294.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Oct;19(8):572-6 [17624747.001]
  • [Cites] Drugs. 2007;67(15):2257-76 [17927287.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):715-20 [18245531.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncologist. 2008;13 Suppl 2:14-8 [18434633.001]
  • [Cites] Oncologist. 2008;13 Suppl 2:32-40 [18434637.001]
  • [Cites] J Magn Reson Imaging. 2008 May;27(5):1109-13 [18425832.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6656-62 [18927308.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):449-57 [19190116.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1153-61 [19114300.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4188-96 [19652065.001]
  • [Cites] Mar Drugs. 2009;7(3):331-40 [19841717.001]
  • [Cites] Anticancer Drugs. 2010 Jan;21(1):113-9 [19887935.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • (PMID = 21116412.001).
  • [ISSN] 1660-3397
  • [Journal-full-title] Marine drugs
  • [ISO-abbreviation] Mar Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  • [Other-IDs] NLM/ PMC2992998
  • [Keywords] NOTNLM ; advanced / chemotherapy / metastatic / soft tissue sarcoma / trabectedin
  •  go-up   go-down


40. Penel N, Watelle F, Vanhuyse M, Adenis A: [Treatment of adult patients with metastatic sarcoma: current shift in concepts]. Bull Cancer; 2010 Jun;97(6):687-91
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult patients with metastatic sarcoma: current shift in concepts].
  • We describe herein the current concepts tested in clinical trials dedicated to patients with metastatic soft tissue sarcomas: identify predictive factors under anthracyclin-based regimens, identify patients beneficing from polychemotherapy, benefit of maintenance treatment, use of non-progression rate rather than response rate for selecting new drugs, histology-tailored or biological target-tailored second-line treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Doxorubicin / administration & dosage. Humans. Sirolimus / administration & dosage. Sirolimus / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20462829.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 48Z35KB15K / ridaforolimus; 80168379AG / Doxorubicin; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


41. Tunn PU, Kettelhack C, Dürr HR: Standardized approach to the treatment of adult soft tissue sarcoma of the extremities. Recent Results Cancer Res; 2009;179:211-28
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardized approach to the treatment of adult soft tissue sarcoma of the extremities.
  • Soft tissue sarcomas are very rare tumors.
  • Furthermore, universally accepted treatment protocols for adult patients are lacking.
  • Several prognostic factors have been identified, including grading, tumor size and development of metastatic disease; however, the relevance of other important aspects in the treatment of patients with soft tissue sarcomas remains unknown or subject to controversy.
  • [MeSH-major] Extremities / pathology. Extremities / surgery. Sarcoma / therapy
  • [MeSH-minor] Adult. Humans

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230542.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 84
  •  go-up   go-down


42. Lee GW, Kim TH, Min HJ, Kim HJ, Jung WT, Lee OJ, Ko GH: Unusual gastrointestinal metastases from an alveolar soft part sarcoma. Dig Endosc; 2010 Apr;22(2):137-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual gastrointestinal metastases from an alveolar soft part sarcoma.
  • Alveolar soft part sarcoma (ASPS) is a rare subtype of soft tissue sarcoma that occurs predominantly in young patients.
  • The common metastatic sites from an ASPS include the lung, brain and bone.
  • [MeSH-major] Jejunal Neoplasms / secondary. Sarcoma, Alveolar Soft Part / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Endoscopy, Digestive System. Humans. Intussusception / diagnosis. Intussusception / etiology. Intussusception / therapy. Male. Young Adult

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447209.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


43. Saithna A, Pynsent PB, Grimer RJ: Retrospective analysis of the impact of symptom duration on prognosis in soft tissue sarcoma. Int Orthop; 2008 Jun;32(3):381-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of the impact of symptom duration on prognosis in soft tissue sarcoma.
  • The objective was to assess whether time to diagnosis is influenced by patient/tumour-related factors and whether or not duration of symptoms has any impact on survival in soft tissue sarcoma.
  • Of 1,508 patients, 159 had metastatic disease at diagnosis and were excluded from analyses.
  • Patient and tumour-related factors significantly associated with longer symptom duration were low-grade, subcutaneous tumours, and epithelioid or synovial sarcoma.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4344-52 [12409334.001]
  • [Cites] Eur J Surg Oncol. 2003 Jun;29(5):440-5 [12798748.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Oct;24(10):1583-8 [3208802.001]
  • [Cites] BMJ. 2005 Sep 17;331(7517):590 [16166112.001]
  • [Cites] Ann R Coll Surg Engl. 2005 May;87(3):171-3 [15901376.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1959-70 [15870714.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):443-8 [15837054.001]
  • (PMID = 17377790.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2323426
  •  go-up   go-down


44. Kasper B: Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. Rev Recent Clin Trials; 2007 Sep;2(3):206-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma.
  • Soft tissue sarcomas are a heterogeneous group of tumours arising predominantly from the embryonic mesoderm.
  • They account for less than 1% of all adult malignancies.
  • The prognosis of patients with advanced metastatic soft tissue sarcoma remains poor with a disease-free survival at 5 years less than 10%.
  • Complete resection remains the major factor in providing cure with limited benefits in local tumour control by radiotherapy and only minimal benefit of systemic therapy for metastatic disease.
  • Moreover, we give an overview on the emerging compounds for patients with soft tissue sarcoma including recent developments of targeted therapy focusing on antiangiogenic and immunomodulatory drugs, Bcl-2 antisense therapy, raf kinase and mTOR inhibition, minor groove binders, and other agents being developed.
  • [MeSH-major] Sarcoma / therapy


45. Grenader T, Goldberg A, Hadas-Halperin I, Gabizon A: Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs; 2009 Jan;20(1):15-20
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
  • Doxorubicin and ifosfamide are currently considered the cornerstones of treatment for advanced soft tissue sarcomas (STSs).
  • Of the 11 patients, seven received no earlier systemic therapy for their sarcoma.
  • PLD is active and safe for long-term treatment of metastatic STSs and may be important in maintaining response.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / analogs & derivatives. Polyethylene Glycols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342997.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


46. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol; 2007 Jul 20;25(21):3144-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
  • PURPOSE: Single-agent doxorubicin remains the standard treatment for advanced soft tissue sarcomas.
  • PATIENTS AND METHODS: This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days.
  • CONCLUSION: Single-agent doxorubicin remains the treatment of choice for patients with advanced soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Doxorubicin / administration & dosage. Ifosfamide / administration & dosage. Sarcoma / drug therapy. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


47. Rehders A, Peiper M, Stoecklein NH, Alexander A, Boelke E, Knoefel WT, Rogiers X: Hepatic metastasectomy for soft-tissue sarcomas: is it justified? World J Surg; 2009 Jan;33(1):111-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastasectomy for soft-tissue sarcomas: is it justified?
  • BACKGROUND: Except for patients with gastrointestinal stromal tumors (GIST), systemic chemotherapy in patients with liver metastasis of soft-tissue sarcoma (STS) is not effective.
  • RESULTS: Twenty-seven of 45 patients with liver metastasis underwent hepatic resection; 59% of these patients had a solitary metastasis, 22% had two metastases, and 18% had three or more metastatic nodules.
  • [MeSH-major] Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Neoplasm Staging. Reoperation. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949511.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H, Maki RG: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol; 2005 Oct 1;23(28):7135-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
  • PURPOSE: To evaluate the antitumor activity and tolerability of bevacizumab and doxorubicin in patients with metastatic soft-tissue sarcoma (STS).
  • Seventeen patients with metastatic STS were treated with doxorubicin at 75 mg/m2 intravenous (IV) push followed by bevacizumab 15 mg/kg IV every 3 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Doxorubicin / administration & dosage. Female. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192597.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM17105; United States / NCI NIH HHS / CA / P01 CA47179
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 80168379AG / Doxorubicin
  •  go-up   go-down


49. Kasper B, Schmitt T, Wuchter P, Dimitrakopoulou-Strauss A, Ho AD, Egerer G: The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin. Mar Drugs; 2009;7(3):331-40
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
  • BACKGROUND: We used 2-deoxy-2-[(18)F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with advanced and/or metastatic soft tissue sarcoma (STS) undergoing therapy with Ecteinascidin-743 (ET-743, Trabectedin, Yondelis).
  • PATIENTS AND METHODS: The pilot study included nine patients with metastatic STS receiving a minimum of one cycle of treatment with trabectedin.
  • [MeSH-major] Dioxoles / therapeutic use. Positron-Emission Tomography / methods. Sarcoma / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Tetrahydroisoquinolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Metastasis. Pilot Projects. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Mar;231(3):380-6 [10714631.001]
  • [Cites] Onkologie. 2008 Mar;31(3):107-12 [18322413.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):231-42 [11234874.001]
  • [Cites] J Nucl Med. 2001 May;42(5):713-20 [11337565.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3156-64 [12118030.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2012-20 [12957455.001]
  • [Cites] Oncology. 2003;65 Suppl 2:80-4 [14586155.001]
  • [Cites] Onkologie. 2004 Feb;27(1):23-30 [15007245.001]
  • [Cites] Nucl Med Commun. 2004 May;25(5):433-8 [15100500.001]
  • [Cites] J Nucl Med. 2004 Sep;45(9):1480-7 [15347714.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):623-48; discussion 649-50 [2013803.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] J Nucl Med. 1997 Nov;38(11):1818-23 [9374364.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3481-7 [9396401.001]
  • [Cites] J Nucl Med. 1998 Feb;39(2):250-4 [9476930.001]
  • [Cites] Eur J Nucl Med. 1999 Jun;26(6):599-605 [10369945.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):286-94 [15650639.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):339-48 [15578712.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5420-3 [16109999.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):369-73 [16721133.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • (PMID = 19841717.001).
  • [ISSN] 1660-3397
  • [Journal-full-title] Marine drugs
  • [ISO-abbreviation] Mar Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 114899-77-3 / trabectedin
  • [Other-IDs] NLM/ PMC2763103
  • [Keywords] NOTNLM ; RECIST / fluorodeoxyglucose / positron emission tomography / soft tissue sarcoma / trabectedin
  •  go-up   go-down


50. Ryzewicz M, McLoughlin HA, Freudenberger C, Williams A, Lindeque B: Unusual metastases from extremity soft tissue sarcomas. Orthopedics; 2008 May;31(5):439
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual metastases from extremity soft tissue sarcomas.
  • The most common metastatic route for extremity soft-tissue sarcomas is via the venous system to the lungs.
  • Metastases to other sites such as the brain, liver, and soft tissue distant from the primary tumor are rare.
  • A tumor registry, prospectively kept since 1986, was reviewed for unusual metastatic spread.
  • Of 3671 tumors, 346 high-grade extremity soft-tissue sarcomas were evaluated.
  • Based on these findings, a different strategy for follow-up of patients after treatment of a high-grade extremity soft-tissue sarcoma is suggested.
  • [MeSH-major] Extremities. Risk Assessment / methods. Sarcoma / epidemiology. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Colorado / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Rare Diseases. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292327.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C: An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs; 2006 May;24(3):249-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
  • BACKGROUND: The number of effective cytotoxic agents for the treatment of patients with metastatic adult type soft tissue sarcoma (STS) is limited, when patients have failed anthracyline-based chemotherapy.
  • All patients had received at least one prior treatment regimen (range, 1-6) for metastatic disease containing anthracyclines (n = 15) and ifosfamide (n = 11).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133789.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


52. Takeuchi A, Tsuchiya H, Yamamoto N, Hayashi K, Yamauchi K, Kawahara M, Miyamoto K, Tomita K: Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res; 2007 Sep-Oct;27(5B):3489-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome.
  • The present study was performed to assess the efficacy of caffeine-potentiated chemotherapy for high-grade soft tissue sarcoma (STS).
  • PATIENTS AND METHODS: A non-randomised prospective clinical trial was initiated for 90 patients with non-metastatic (stages II and III) or metastatic (stage IV) STS.
  • The local recurrence rate was 23.7% in stages II and III and 13.6% in stage IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Caffeine / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Drug Synergism. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972506.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


53. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, Eary JF: Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer; 2005 Jan 15;103(2):339-48
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
  • BACKGROUND: Patients with high-grade soft tissue sarcomas are at high risk of developing local disease recurrence and metastatic disease.
  • CONCLUSIONS: The FDG-PET scan was found to be a useful method with which to predict the outcomes of patients with high-grade extremity soft tissue sarcomas treated with chemotherapy.
  • The FDG-PET scan showed promise as a tool to identify the patients with sarcoma who are most likely to benefit from chemotherapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Positron-Emission Tomography. Sarcoma / drug therapy. Sarcoma / radionuclide imaging. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Female. Follow-Up Studies. Humans. Lower Extremity. Male. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Neoplasm Staging. Orthopedic Procedures / methods. Probability. Prospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis. Treatment Outcome. Upper Extremity

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15578712.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA65537; United States / NCI NIH HHS / CA / CA76930; United States / NCI NIH HHS / CA / CA87721
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


54. Garcia JJ, Kramer MJ, O'Donnell RJ, Horvai AE: Mismatch repair protein expression and microsatellite instability: a comparison of clear cell sarcoma of soft parts and metastatic melanoma. Mod Pathol; 2006 Jul;19(7):950-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mismatch repair protein expression and microsatellite instability: a comparison of clear cell sarcoma of soft parts and metastatic melanoma.
  • Clear cell sarcoma of soft parts is a rare soft tissue malignancy that shows phenotypic overlap with cutaneous melanoma but can be distinguished by the presence of a t(12;22) translocation.
  • Microsatellite instability (MSI), a variation in the lengths of short repeat DNA segments in the genome, has been implicated in melanoma tumorigenesis, but is rare or absent in clear cell sarcoma.
  • To determine if the association between MMR defects and MSI extends to clear cell sarcoma, we compared a group of nine clear cell sarcomas to 11 metastatic melanomas on the basis of MSI and the expression of MMR proteins.
  • Immunohistochemistry was evaluated on formalin-fixed paraffin-embedded tissue for hMLH1, hMHS2 and hMSH6.
  • MSI was present in only 1/9 (11%) clear cell sarcoma case and in 8/11 (73%) melanoma cases.
  • Clear cell sarcoma and metastatic melanoma differed significantly with respect to the presence of MSI (P=0.010) and staining for hMLH1 and/or hMSH2 (P=0.014) but not hMSH6 (P=0.57).
  • Mismatch repair, and consequently genomic instability may contribute to tumorigenesis in melanoma but not clear cell sarcoma.
  • Immunostaining for hMLH1 and hMSH2 and MSI analysis may be helpful in the differential diagnosis of large soft tissue or visceral malignancies with melanocytic differentiation.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Neoplastic. Genomic Instability. Melanoma / genetics. Microsatellite Repeats / genetics. Nuclear Proteins / metabolism. Sarcoma, Clear Cell / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Polymerase Chain Reaction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619000.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


55. Fernebro J, Carneiro A, Rydholm A, Domanski HA, Karlsson A, Borg A, Nilbert M: Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma. Sarcoma; 2008;2008:431019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma.
  • Purpose. Patients with soft tissue sarcomas (STS) are at increased risk of second primary malignancies, including a second STS, but distinction between metastases and a second primary STS is difficult.
  • In an unsupervised hierarchical cluster analysis, similar genomic profiles and close clustering between the first and subsequent STS were identified in 5 cases, suggesting metastatic disease, whereas the tumors from the remaining 8 patients did not cluster and showed only weak pairwise correlation, suggesting development of second primary STS.
  • Discussion. The similarities and dissimilarities identified in the first and second STS suggest that genetic profiles can be used to distinguish soft tissue metastases from second primary STS.
  • The demonstration of genetically different soft tissue sarcomas in the same patient suggests independent tumor origin and serves as a reminder to consider development of second primary STS, which has prognostic and therapeutic implications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmic Genet. 1997 Mar;18(1):27-34 [9134547.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):960-5 [9307198.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1851-9 [7636528.001]
  • [Cites] Clin Exp Metastasis. 1993 Sep;11(5):401-8 [8375115.001]
  • [Cites] Ann Surg. 1993 Jan;217(1):72-7 [8424704.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] Acta Orthop Scand. 1992 Feb;63(1):98-9 [1738982.001]
  • [Cites] Jpn J Surg. 1986 Jul;16(4):277-83 [3773360.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1758-65 [15073867.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 1;150(1):27-32 [15041220.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):357-63 [14996857.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1947-57 [14584079.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1619-30 [11822764.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):1-12 [11752241.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):978-84 [11598167.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1363-71 [11283938.001]
  • [Cites] Lab Invest. 2001 Feb;81(2):211-5 [11232643.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2788-93 [10914725.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8984-93 [16982739.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):986-90 [17008869.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jun;119(2):102-8 [10867143.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Sep;169(2):94-101 [16938566.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):476-83 [16421424.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):545-51 [16125217.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Oct;27(10):517-20 [16217253.001]
  • [Cites] Jpn J Clin Oncol. 2005 Aug;35(8):444-52 [16024533.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2391-6 [15852362.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2272-9 [15800318.001]
  • [Cites] Virchows Arch. 2005 Mar;446(3):251-8 [15731925.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):591-7 [15696129.001]
  • [Cites] Bioinformatics. 2003 Sep 1;19(13):1714-5 [15593402.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2633-5 [15494976.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):323-31 [10398425.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):985-90 [9736047.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):37-40 [9524706.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):603-9 [7884422.001]
  • (PMID = 19197386.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2634844
  •  go-up   go-down


56. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
  • BACKGROUND: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.
  • METHODS: Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database.
  • Patients with Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and gastrointestinal stromal tumors were excluded from the study.
  • The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • An objective response was reported in 33% of patients (53% in those with synovial sarcoma); 22% had stable disease and 45% derived 'clinical benefit' (objective responses + stable disease for >or= 6 months).
  • Synovial sarcoma and liposarcoma subtypes have a better prognosis.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Manoso MW, Frassica DA, Deune EG, Frassica FJ: Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas. J Surg Oncol; 2005 Sep 1;91(3):153-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas.
  • BACKGROUND AND OBJECTIVES: Unplanned excisions of soft-tissue sarcomas of the extremities occur commonly.
  • Our goal was to evaluate the presence of residual disease, the treatment outcomes as they relate to local and distant recurrence and 5-year survival, and the limb functional outcomes in patients with unplanned sarcoma excision who were treated with re-excision and adjuvant therapy.
  • METHODS: Between 1993 and 1999, 42 patients presented to our institution after unplanned excision of soft-tissue sarcomas.
  • Of those 42 patients, 38 without gross residual disease or metastatic lesions formed the basis of this review.
  • Univariate analysis showed that stage-III disease (American Joint Committee on Cancer classification of soft-tissue sarcomas), lesions below the fascia, a histologic high-grade, and the development of organ metastasis were statistically significant factors for mortality.
  • Stage-III disease also was significant for mortality on multivariate analysis.
  • Only stage-III disease was significant for the development of local recurrence.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Baltimore / epidemiology. Combined Modality Therapy. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Reoperation. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16118773.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Leahy M, Ray-Coquard I, Verweij J, Le Cesne A, Duffaud F, Hogendoorn PC, Fowst C, de Balincourt C, di Paola ED, van Glabbeke M, Judson I, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer; 2007 Jan;43(2):308-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
  • The study aimed to assess the efficacy and safety of brostallicin, a new DNA minor groove binder, at a dose of 10mg/m2, intravenous (i.v.) every three weeks, in patients with advanced or inoperable soft tissue sarcoma (STS) and gastrointestinal stromal tumour (GIST) failing first line therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Gastrointestinal Stromal Tumors. Guanidines / administration & dosage. Pyrroles / administration & dosage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17095209.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Guanidines; 0 / Pyrroles; RPC6R41K4I / brostallicin
  •  go-up   go-down


59. Asavamongkolkul A, Waikakul S, Phimolsarnti R, Kiatisevi P, Wangsaturaka P: Endoprosthetic reconstruction for malignant bone and soft-tissue tumors. J Med Assoc Thai; 2007 Apr;90(4):706-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoprosthetic reconstruction for malignant bone and soft-tissue tumors.
  • BACKGROUND: Nowadays, the results of the management of malignant bone and soft-tissue tumors have been dramatically improved because of the advance in imaging, chemotherapy, radiation therapy, and surgical techniques.
  • OBJECTIVE: To report the preliminary results of 32 endoprosthetic reconstructions following malignant bone and soft-tissue tumor resection.
  • From March 1994 to July 2006, 32 endoprosthetic reconstructions were performed on 30 patients following malignant bone or soft-tissue tumor removal.
  • The diagnosis was conventional osteosarcoma in 16 patients, parosteal osteosarcoma in two patients, chondrosarcoma in two patients, leiomyosarcoma in two patients, failed allograft in two patients and one patient each of periosteal osteosarcoma, Ewing's sarcoma, Gorham's disease, synovial sarcoma, malignant fibrous histiocytoma, metastatic renal cell carcinoma, and prosthetic loosening.
  • CONCLUSION: Endoprosthetic reconstruction could yield satisfactory results as a wide excision and limb-salvage for patients with malignant bone and soft-tissue tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Osteosarcoma / surgery. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Prostheses and Implants. Prosthesis Implantation / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487125.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


60. Kim YD, Lee CH, Lee MK, Jeong YJ, Kim JY, Park DY, Sol MY: Primary alveolar soft part sarcoma of the lung. J Korean Med Sci; 2007 Apr;22(2):369-72
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary alveolar soft part sarcoma of the lung.
  • Alveolar soft part sarcoma (ASPS) is a rare epithelial-like soft tissue sarcoma.
  • Primary pulmonary involvement of this sarcoma, without evidence of soft tissue tumor elsewhere, is very exceptional.
  • After 5 months, three metastatic lesions, involving lumbar vertebrae and occipital scalp, were found.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / radiography. Pulmonary Alveoli / pathology. Pulmonary Alveoli / radiography. Sarcoma / pathology. Sarcoma / radiography
  • [MeSH-minor] Adult. Female. Humans. Rare Diseases / pathology. Rare Diseases / radiography. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / radiography

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2000 May;58(4):319-23 [10838498.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):179-92 [11438465.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):1-13 [2642727.001]
  • [Cites] Acta Pathol Jpn. 1991 Oct;41(10):771-7 [1812692.001]
  • [Cites] Hum Pathol. 1993 Sep;24(9):1030-4 [8253458.001]
  • [Cites] Ann Pathol. 1996;16(1):49-52 [8652002.001]
  • [Cites] Adv Anat Pathol. 1999 May;6(3):125-39 [10342010.001]
  • (PMID = 17449953.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693611
  •  go-up   go-down


61. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs; 2006 Sep;24(5):435-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
  • BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins.
  • CONCLUSIONS: Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcoma patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Phosphorylcholine / analogs & derivatives. Sarcoma / drug therapy
  • [MeSH-minor] Academies and Institutes. Adult. Aged. Canada. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasms / drug therapy


62. Kasper B, Ho AD, Egerer G: Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? Oncology; 2005;68(2-3):115-21
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
  • Sarcomas represent a rare and heterogeneous disease, and the prognosis of patients with unresectable or advanced metastatic bone and especially soft-tissue sarcomas remains poor, with a disease-free survival of less than 10% at 5 years.
  • However, all studies comprised small patient cohorts and included very heterogeneous histological subtypes of soft-tissue sarcoma.
  • In this review, we provide an overview of the literature concerning high-dose chemotherapy with hematopoietic stem cell support in the treatment of bone and soft-tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Osteosarcoma / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Neoplasms / drug therapy. Bone Neoplasms / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hematopoietic Stem Cell Transplantation. Humans. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Male. Middle Aged. Retroperitoneal Neoplasms / drug therapy. Retrospective Studies. Skin Neoplasms / drug therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15886503.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 35
  •  go-up   go-down


63. Koontz BF, Clough RW, Halperin EC: Palliative radiation therapy for metastatic Ewing sarcoma. Cancer; 2006 Apr 15;106(8):1790-3
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy for metastatic Ewing sarcoma.
  • BACKGROUND: Although radiotherapy is an accepted component of curative treatment for Ewing sarcoma (EWS), to the authors' knowledge, there are scant data evaluating its use for palliation.
  • METHODS: Between 1980 and 2002, 21 patients with metastatic EWS received palliative radiotherapy.
  • RESULTS: Sixty-three metastatic sites were irradiated (median dose, 30 gray [Gy]; range, 4.5-68.5 Gy), and a median of 3 sites were treated per patient (range, 1-16 sites per patient).
  • Censoring this survivor, patients lived for a median of 1.0 year after metastatic diagnosis (range, from 17 days to 6.8 years), 41 days of which were spent in treatment (range, 1-93 days).
  • CONCLUSIONS: It was possible to treat metastatic EWS effectively with palliative radiotherapy.
  • [MeSH-major] Palliative Care. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / secondary
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Child. Child, Preschool. Female. Humans. Male. Radiotherapy Dosage. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / secondary. Survival Rate

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16534788.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Bui-Nguyen B, Italiano A, Delva F, Toulmond M: [Adjuvant chemotherapy of adults soft tissue sarcomas]. Bull Cancer; 2010 Jun;97(6):673-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy of adults soft tissue sarcomas].
  • The main progress in the management of soft tissue sarcomas have been obtained in the field of local control.
  • Although the main evolutive, vital, risk of these diseases is metastatic dissemination, efficacy of adjuvant chemotherapy remains a controversial issue.
  • New therapeutic strategies are to be developed to prevent metastases in soft tissue sarcomas.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20547481.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


65. Nathan PC, Tsokos M, Long L, Bernstein D, Wexler LH, Mackall CL, Helman LJ: Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Pediatr Blood Cancer; 2005 May;44(5):449-54
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience.
  • BACKGROUND: The survival of children and adolescents with advanced (unresectable or metastatic) nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) is poor.
  • RESULTS: Of the 25 patients who were treated over the study period, 15 had metastatic disease and 10 had unresectable or incompletely resected disease at presentation.
  • [MeSH-major] Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Doxorubicin / therapeutic use. Female. Humans. Infant. Male. Neoplasm Metastasis. Remission Induction / methods. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2004 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2005 Aug;45(2):226-7; author reply 228 [15782404.001]
  • (PMID = 15547929.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


66. Stroppa E, Bertuzzi A, Di Comite G, Mussi C, Lutman RF, Barbato A, Santoro A: Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. Invest New Drugs; 2010 Dec;28(6):834-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.
  • OBJECTIVE: The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas.
  • METHODS: Cohorts of four patients with metastatic soft tissue sarcomas received up to five cycles of intravenous ifosfamide 3000 mg/m2 on days 1- 3 in combination with escalating doses of intravenous Myocet on day 1 every 3 weeks until dose limiting toxicity (DLT) in at least one patient.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Ifosfamide / therapeutic use. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582371.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


67. Kontogeorgakos VA, Martinez S, Dodd L, Brigman BE: Extremity soft tissue sarcomas presented as hematomas. Arch Orthop Trauma Surg; 2010 Oct;130(10):1209-14
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremity soft tissue sarcomas presented as hematomas.
  • INTRODUCTION: Soft tissue sarcoma (STS) with extensive intra-tumoral hemorrhage is an infrequently described entity, usually misdiagnosed as intra-muscular hematoma.
  • MATERIALS AND METHODS: We retrospectively identified 15 patients, with initial clinical or imaging diagnosis of hematoma, or hematoma versus hemorrhagic sarcoma, although final diagnosis of high-grade STS was established in all cases.
  • Ten patients were referred for further evaluation with the initial diagnosis of muscle strain/hematoma, hematoma versus abscess in one, whereas four were referred for soft tissue mass evaluation.
  • One patient had lung metastatic disease at presentation and eight developed lung metastases within a median time of 7 months.
  • The evacuation of hematomas should include pathologic examination of tissue.
  • Prognosis is dismal due to early metastatic disease.
  • [MeSH-major] Hematoma / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Hemangiosarcoma / diagnosis. Histiocytoma, Malignant Fibrous / diagnosis. Humans. Male. Middle Aged. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Sarcoma, Synovial

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838719.001).
  • [ISSN] 1434-3916
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. Lazar AJ, Das P, Tuvin D, Korchin B, Zhu Q, Jin Z, Warneke CL, Zhang PS, Hernandez V, Lopez-Terrada D, Pisters PW, Pollock RE, Lev D: Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res; 2007 Dec 15;13(24):7314-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis-promoting gene patterns in alveolar soft part sarcoma.
  • PURPOSE: We examined a cohort of patients with alveolar soft part sarcoma (ASPS) treated at our institution and showed the characteristic ASPSCR1-TFE3 fusion transcript in their tumors.
  • In the three frozen samples subjected to an angiogenesis oligoarray, 18 angiogenesis-related genes were up-regulated in tumor over adjacent normal tissue.
  • CONCLUSION: ASPS is a highly vascular and metastatic tumor with a surprisingly favorable outcome; therapeutically resistant metastases drive mortality.
  • [MeSH-major] Neovascularization, Pathologic / genetics. Sarcoma, Alveolar Soft Part / genetics
  • [MeSH-minor] Adult. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094412.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASPSCR1 protein, human; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / TFE3 protein, human
  •  go-up   go-down


69. Singh RP, Grimer RJ, Bhujel N, Carter SR, Tillman RM, Abudu A: Adult head and neck soft tissue sarcomas: treatment and outcome. Sarcoma; 2008;2008:654987

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult head and neck soft tissue sarcomas: treatment and outcome.
  • We have retrospectively analysed the experience of a musculoskeletal oncological unit in the management of adult head and neck soft tissue sarcomas from 1990 to 2005.
  • 42% of the patients developed local recurrence and 42% developed metastatic disease usually in the lungs.
  • Adult head and neck soft tissue sarcomas have a high mortality rate with a high risk of local recurrence and metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Aug 15;89(4):868-72 [10951351.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):377-88, vii [11370499.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Apr;12(2):379-417 [12916461.001]
  • [Cites] World J Surg. 2003 Jul;27(7):875-83 [14509522.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):619-28 [15172935.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):259-63 [15923798.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Laryngoscope. 2006 May;116(5):780-5 [16652087.001]
  • [Cites] Head Neck. 2007 Aug;29(8):731-40 [17274049.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):697-702 [8033050.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Sep;120(9):981-6 [8074826.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):201-7 [8318414.001]
  • [Cites] Head Neck. 2005 Oct;27(10):916-22 [16136585.001]
  • (PMID = 18382622.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2276692
  •  go-up   go-down


70. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M: Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline. Curr Oncol; 2007 Aug;14(4):144-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline.
  • QUESTIONS: In adult patients with inoperable locally advanced or metastatic soft-tissue sarcoma, do combination chemotherapy regimens containing ifosfamide have an advantage in terms of response rate, time to progression, or survival, as compared with similar regimens without ifosfamide when used as first-line therapy?
  • PERSPECTIVES: The prognosis for patients with inoperable or meta-static soft-tissue sarcoma (sts) remains grim.
  • A number of studies have suggested a schedule and a dose-response relationship for ifosfamide in metastatic sts.
  • Given the limited effective therapeutic options available for patients with metastatic sts, the Sarcoma Disease Site Group (dsg) felt that a need existed to more specifically evaluate the potential benefits of ifosfamide-containing combination chemotherapy in that setting.
  • The Sarcoma dsg developed an evidence-based series report through systematic review, evidence synthesis, and input from practitioners across Ontario.
  • The report was reviewed and approved by the Sarcoma dsg, which comprises medical oncologists, radiation oncologists, surgeons, methodologists, and patient representatives.
  • PRACTICE GUIDELINE: In patients with metastatic sts, the addition of ifosfamide to standard first-line doxorubicin-containing regimens is not recommended over single-agent doxorubicin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1995 Jun;59(2):110-5 [7776651.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Am J Clin Oncol. 1994 Dec;17(6):480-4 [7977164.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):669-72 [8240997.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] Cancer Chemother Pharmacol. 1983;11(2):69-72 [6414732.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] Cancer. 2000 Jul 1;89(1):177-80 [10897015.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2077-80 [10928155.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2397-406 [12460784.001]
  • [Cites] Ann Oncol. 1992 Jun;3(6):487-8 [1498067.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(2):100-4 [1600589.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 4):41-9 [2110385.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):126-31 [2491883.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):863-6 [2498525.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1655-9 [2681554.001]
  • [Cites] J Natl Cancer Inst. 1989 Oct 4;81(19):1496-9 [2778839.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):49-52 [3124971.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Sep;24(9):1439-43 [3181268.001]
  • [Cites] Am J Clin Oncol. 1993 Aug;16(4):332-7 [8328412.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S180-4 [8453694.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S204-9 [8453699.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S213-6 [8453701.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31 Suppl 2:S222-7 [8453703.001]
  • [Cites] Cancer Invest. 1993;11(2):135-9 [8462014.001]
  • [Cites] Oncology. 1996 Jan-Feb;53(1):58-63 [8570133.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):675-82 [8616759.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1551-8 [9389914.001]
  • [Cites] Cancer Invest. 1998;16(5):297-302 [9627675.001]
  • (PMID = 17710206.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1948866
  •  go-up   go-down


71. Ryan CW, Dolan ME, Brockstein BB, McLendon R, Delaney SM, Samuels BL, Agamah ES, Vokes EE: A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol; 2006 Nov;58(5):634-9
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
  • We performed a phase II study to explore the activity of O6-BG in combination with BCNU in patients with advanced soft tissue sarcoma.
  • EXPERIMENTAL DESIGN: Informed consent was obtained from patients with metastatic soft tissue sarcoma naïve to systemic chemotherapy (adjuvant chemotherapy allowed).
  • Immunohistochemical estimation of MGMT expression from archival tissue ranged from 20 to 99% positive staining cells.
  • Further development of this regimen and dose for the treatment of soft tissue sarcoma is not warranted due to the lack of objective responses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Carmustine / administration & dosage. Carmustine / adverse effects. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / adverse effects. Female. Gastrointestinal Stromal Tumors / drug therapy. Guanine / administration & dosage. Guanine / adverse effects. Guanine / analogs & derivatives. Humans. Immunohistochemistry. Infant. Injections, Intravenous. Leiomyosarcoma / drug therapy. Male. Middle Aged. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Survival Analysis. Tachycardia, Supraventricular / chemically induced. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520986.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01CA63187
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  •  go-up   go-down


72. Kara IO, Gonlusen G, Sahin B, Ergin M, Erdogan S: A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process? Saudi Med J; 2005 Aug;26(8):1190-6
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
  • OBJECTIVE: Within soft-tissue sarcoma, primitive neuroectodermal tumors have been shown to cover a wide spectrum of small round cell sarcomas, including Ewing's sarcomas (ES) and primitive neuroectodermal tumors (PNET).
  • Five were diagnosed as metastatic disease whereas 23 were diagnosed as non-metastatic disease at admission.
  • There was no significant correlation between c-kit expression and gender, localization, metastatic status, treatment modalities and tumor.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / metabolism. Neuroectodermal Tumors, Primitive / pathology. Proto-Oncogene Proteins c-kit / metabolism. Sarcoma, Ewing / metabolism. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Protein-Tyrosine Kinases / antagonists & inhibitors. Retrospective Studies

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127511.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


73. Fox BD, Patel A, Suki D, Rao G: Surgical management of metastatic sarcoma to the brain. J Neurosurg; 2009 Jan;110(1):181-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of metastatic sarcoma to the brain.
  • OBJECT: Metastatic sarcoma to the brain is rare and represents a therapeutic challenge due to its relative resistance to radio- and chemotherapy.
  • The authors reviewed a series of patients with metastatic sarcoma to the brain treated surgically to determine outcomes and identify predictors of survival in these patients.
  • METHODS: A retrospective review of prospectively collected data was undertaken on patients undergoing surgery between 1993 and 2005 for metastatic sarcoma to the brain at The University of Texas, M.D.
  • RESULTS: During the study period, 62 patients underwent 84 operations for metastatic sarcoma to the brain.
  • In multivariate and univariate analysis, control of systemic disease, and sarcomas originating from bone, cartilage, or soft tissue were predictors of survival.
  • In patients with alveolar soft-part sarcoma, there was a significantly increased survival advantage compared with all other histological subgroups.
  • CONCLUSIONS: The authors' results suggest that in selected patients, resection of metastatic sarcoma to the brain is associated with a relatively low risk of operative death and results in improvement in neurological function.
  • Patients with systemic control of their primary disease and certain histological subtypes (specifically alveolar soft-part sarcoma) have improved overall and progression-free survival.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Neurosurgical Procedures. Sarcoma / secondary. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Predictive Value of Tests. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult


74. Schreiber D, Bell RS, Wunder JS, O'Sullivan B, Turcotte R, Masri BA, Davis AM: Evaluating function and health related quality of life in patients treated for extremity soft tissue sarcoma. Qual Life Res; 2006 Nov;15(9):1439-46
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating function and health related quality of life in patients treated for extremity soft tissue sarcoma.
  • OBJECTIVE: To evaluate how functional disability impacts on health related quality of life (HRQOL) of patients with extremity soft tissue sarcoma (STS) at 1 year post-surgery.
  • Patients were over 16 years, non-metastatic at diagnosis, and had limb salvage surgery.
  • [MeSH-major] Activities of Daily Living. Quality of Life. Sarcoma / psychology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Canada. Databases, Factual. Disability Evaluation. Female. Humans. Linear Models. Male. Middle Aged. Multicenter Studies as Topic. Postoperative Period. Severity of Illness Index. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16732468.001).
  • [ISSN] 0962-9343
  • [Journal-full-title] Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
  • [ISO-abbreviation] Qual Life Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


75. Leidinger B, Heyse T, Schuck A, Buerger H, Mommsen P, Bruening T, Fuchs S, Gosheger G: High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy. BMC Cancer; 2006;6:160
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy.
  • BACKGROUND: The risk of metastasis and the survival in patients with primary extremity soft tissue sarcomas is worse when tumour size is large and the grade of malignancy is high.
  • The question arises if the kind of RTX in the absence of chemotherapy influences the outcome concerning local control, metastatic disease, survival and complications.
  • METHODS: We retrospectively reviewed the clinical outcome of 233 patients with a primary extremity soft tissue sarcoma treated between 1990 - 2000 with a mean follow-up of 35.8 (4-120) months in our institute.
  • 41 patients had high grade, deep and large tumours (>8 cm), an AJCC stage III (no evidence of metastasis prior to treatment) and were treated with limb salvage surgery and irradiation but stayed without additional chemotherapy.
  • RESULTS: 56% (23/41) of the population developed metastatic disease, 24% (10/41) local recurrence.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):177-89 [11953609.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):431-6 [12099655.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4472-7 [12431971.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1872-80 [12932665.001]
  • [Cites] Acta Oncol. 2003;42(5-6):516-31 [14596510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):522-6 [15380587.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2659-67 [3995476.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):172-7 [3940616.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):484-91 [3942981.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):480-8 [3819810.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1500-4 [3040219.001]
  • [Cites] J Bone Joint Surg Am. 1987 Sep;69(7):1074-8 [3654700.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):693-9 [3350724.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):854-62 [3367188.001]
  • [Cites] Can J Surg. 1989 Jan;32(1):69-73 [2910383.001]
  • [Cites] Acta Orthop Scand. 1989 Dec;60(6):687-92 [2696323.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):899-906 [2211257.001]
  • [Cites] Ann Surg. 1991 Sep;214(3):328-36; discussion 336-8 [1929613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1485-92 [1938557.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1595-9 [1938569.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Jan;4(1):36-43 [1736977.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(3):653-60 [1612967.001]
  • [Cites] Surg Gynecol Obstet. 1993 Feb;176(2):124-34 [8421799.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):223-30 [8468983.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] Eur J Cancer. 1994;30A(6):746-51 [7917531.001]
  • [Cites] J Surg Oncol. 1994 Oct;57(2):111-4 [7934061.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):347-56 [7997728.001]
  • [Cites] Acta Orthop Scand. 1994 Oct;65(5):553-8 [7801762.001]
  • [Cites] Cancer. 1995 May 1;75(9):2299-306 [7712441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85 [7607972.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):90-9 [8606553.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1599-608 [11527684.001]
  • (PMID = 16780601.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550254
  •  go-up   go-down


76. Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, Leu KM, Chandler WF, Baker LH: Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol; 2005 May 20;23(15):3597-604
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
  • PURPOSE: The purpose of this trial was to assess the objective clinical response, toxicity, and time to progression of treatment with 9-Nitro-Camptothecin (9-NC) in patients with advanced chordoma, soft tissue sarcoma (STS), and gastrointestinal stromal tumor (GIST).
  • PATIENTS AND METHODS: Patients with locally advanced and/or metastatic chordoma, STS, or GIST received 9-NC 1.25 mg/m2 orally for 5 consecutive days followed by 2 days of rest.
  • CONCLUSION: 9-NC has modest activity in delaying progression in patients with unresectable or metastatic chordoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / therapeutic use. Chordoma / drug therapy. Neoplasm Invasiveness / pathology. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Chordoma.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908670.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


77. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S: The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist; 2007 Nov;12(11):1351-60
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
  • The treatment outcome of patients with locally advanced and metastatic soft tissue sarcomas is poor.
  • This review addresses the clinical pharmacology, metabolism, and present role of ifosfamide in the treatment of locally advanced and/or metastatic soft tissue sarcomas, excluding gastrointestinal stromal tumors, the Ewing-like sarcomas, and other small blue round cell tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Ifosfamide / pharmacology. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Disease Progression. Doxorubicin / pharmacology. Drug Therapy / methods. Humans. Models, Biological. Neoplasm Metastasis. Treatment Outcome. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055856.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 84
  •  go-up   go-down


78. Suppiah R, Wood L, Elson P, Budd GT: Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs; 2006 Nov;24(6):509-14
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
  • METHODS: Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial.
  • HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Survival Analysis. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791410.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


79. Mocellin S, Rossi CR, Brandes A, Nitti D: Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev; 2006 Feb;32(1):9-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.
  • The therapeutic approach to soft tissue sarcomas (STS) has evolved over the past two decades based on the results from randomized controlled trials, which are guiding physicians in the treatment decision-making process.
  • Despite significant improvements in the control of local disease, a significant number of patients ultimately die of recurrent/metastatic disease following radical surgery due to a lack of effective adjuvant treatments.
  • In addition, the characteristic chemoresistance of STS has compromised the therapeutic value of conventional antineoplastic agents in cases of unresectable advanced/metastatic disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Sarcoma / metabolism. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant. Enzyme Inhibitors / therapeutic use. Genetic Therapy. Growth Substances / metabolism. Humans. Matrix Metalloproteinase Inhibitors. Middle Aged. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338075.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cancer Vaccines; 0 / Enzyme Inhibitors; 0 / Growth Substances; 0 / Matrix Metalloproteinase Inhibitors
  • [Number-of-references] 234
  •  go-up   go-down


80. Garcia JJ, Kramer MJ, Mackey ZB, O'Donnell RJ, Horvai AE: Utility of CD117 immunoreactivity in differentiating metastatic melanoma from clear cell sarcoma. Arch Pathol Lab Med; 2006 Mar;130(3):343-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of CD117 immunoreactivity in differentiating metastatic melanoma from clear cell sarcoma.
  • CONTEXT: Clear cell sarcoma is a malignant soft tissue tumor with melanocytic differentiation.
  • Molecular methods are sometimes necessary to identify the unique t(12; 22)(q13;q12) translocation and differentiate clear cell sarcoma from melanoma.
  • OBJECTIVE: To determine whether CD117 immunoreactivity may be useful in separating melanoma from clear cell sarcoma.
  • DESIGN: We identified 20 tumors listed in our surgical pathology files that were diagnosed as clear cell sarcoma or in which clear cell sarcoma was strongly considered.
  • These were tested for the presence of the t(12;22) translocation by reverse transcriptase/polymerase chain reaction and sequencing from paraffin-embedded tissue.
  • Tumors with a t(12;22) translocation were immunostained with an antibody to CD117 and compared with 16 similarly stained metastatic melanomas.
  • No metastatic melanomas demonstrated t(12;22).
  • Conversely, 10 (63%) of 16 metastatic melanomas were, at least focally, positive for CD117; this difference was significant (P < .001).
  • Interestingly, 3 tumors in which clear cell sarcoma was initially considered as a diagnosis, but which lacked t(12;22), were also positive for CD117.
  • CONCLUSIONS: Reverse transcriptase/polymerase chain reaction, performed on paraffin-embedded tissue, is a useful, rapid tool for identifying the presence of t(12;22) in clear cell sarcoma.
  • The CD117 immunoreactivity may prove useful in the differential diagnosis of deep soft tissue or visceral lesions with melanocytic differentiation; positive staining results exclude clear cell sarcoma, but are compatible with metastatic melanoma.
  • [MeSH-major] Melanoma / diagnosis. Proto-Oncogene Proteins c-kit / analysis. Sarcoma, Clear Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 22. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519562.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


81. Italiano A, Toulmonde M, Lortal B, Stoeckle E, Garbay D, Kantor G, Kind M, Coindre JM, Bui B: "Metronomic" chemotherapy in advanced soft tissue sarcomas. Cancer Chemother Pharmacol; 2010 May;66(1):197-202
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Metronomic" chemotherapy in advanced soft tissue sarcomas.
  • PURPOSE: Angiogenesis plays a crucial role in metastatic progression of soft tissue sarcomas (STS).
  • We report the safety and the efficacy of metronomic chemotherapy in metastatic STS patients.
  • METHODS: The medical charts of 26 metastatic STS patients treated at Institut Bergonie (Bordeaux, France) with metronomic etoposide (100 mg/day orally for 21 consecutive days, repeated every 4 weeks) were reviewed by two independent investigators.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis. Neutropenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182726.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


82. King DM, Hackbarth DA, Kilian CM, Carrera GF: Soft-tissue sarcoma metastases identified on abdomen and pelvis CT imaging. Clin Orthop Relat Res; 2009 Nov;467(11):2838-44
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcoma metastases identified on abdomen and pelvis CT imaging.
  • The current standard of care for patients with extremity soft-tissue sarcomas is to obtain imaging of the chest for staging and surveillance.
  • Our institutional standard of care has been to obtain CT scans of the chest, abdomen, and pelvis to evaluate for metastatic disease.
  • We retrospectively reviewed our sarcoma databases from 2000 to 2008.
  • We included 124 patients with 15 types of extremity soft tissue sarcomas evaluated with CT of the C/A/P.
  • Primary outcomes were (1) location of metastatic disease in relation to (2) sarcoma type.
  • Twenty patients (16%) presented with or developed abdomen/pelvis metastases and 10 of the 15 types of soft tissue sarcomas had abdominal or pelvic metastases.
  • A larger number of patients demonstrated metastatic disease in the abdomen and pelvis than anticipated.
  • We believe routine imaging of the abdomen and pelvic with CT for both staging and surveillance of all types of soft tissue sarcoma should be considered.
  • [MeSH-major] Pelvic Neoplasms / radiography. Sarcoma / secondary. Soft Tissue Neoplasms / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / radiography. Abdominal Neoplasms / secondary. Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Monitoring, Physiologic / methods. Neoplasm Staging. Registries. Retrospective Studies. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):9-14 [10674442.001]
  • [Cites] Radiology. 2008 Jul;248(1):254-63 [18566177.001]
  • [Cites] AJR Am J Roentgenol. 2001 Aug;177(2):289-91 [11461847.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4344-52 [12409334.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Radiology. 2004 May;231(2):393-8 [15031431.001]
  • [Cites] Curr Opin Oncol. 2004 Jul;16(4):328-32 [15187887.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):353-66 [3973646.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1120-7 [7850710.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Oncology (Williston Park). 1997 Sep;11(9):1327-32 [9306421.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):85-92 [9921978.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):389-95 [10023707.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):777-85 [10679646.001]
  • (PMID = 19636646.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2758993
  •  go-up   go-down


83. Ghert MA, Abudu A, Driver N, Davis AM, Griffin AM, Pearce D, White L, O'Sullivan B, Catton CN, Bell RS, Wunder JS: The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol; 2005 Jan;12(1):10-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity.
  • BACKGROUND: The indications for primary amputation of a localized soft tissue sarcoma (STS) of the extremity are not well defined in the literature.
  • RESULTS: Twenty-five (6%) of 413 patients with STS underwent primary amputation: they were older (P = .05), had larger tumors (P = .001), and had a significantly greater risk of developing metastatic disease than patients who underwent limb-sparing procedures (P = .008).
  • Primary amputation was not an independent risk factor for metastatic disease.
  • [MeSH-major] Amputation. Neoplasm Metastasis. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Arm / surgery. Decision Making. Female. Follow-Up Studies. Humans. Leg / surgery. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Jan;12(1):1-2 [15827768.001]
  • (PMID = 15827772.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Ebeling P, Eisele L, Schuett P, Bauer S, Schuette J, Moritz T, Seeber S, Flasshove M: Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. Onkologie; 2008 Feb;31(1-2):11-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
  • INTRODUCTION: Advanced stage/metastatic soft tissue sarcoma (STS) has a poor prognosis especially after failure of the established first-line treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Male. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2008 Feb;31(1-2):6-8 [18268393.001]
  • (PMID = 18268394.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


85. Anderson ME, Hornicek FJ, Gebhardt MC, Raskin KA, Mankin HJ: Alveolar soft part sarcoma: a rare and enigmatic entity. Clin Orthop Relat Res; 2005 Sep;438:144-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar soft part sarcoma: a rare and enigmatic entity.
  • Alveolar soft part sarcoma is a rare malignant tumor with unusual clinical behavior.
  • Treatment of alveolar soft part sarcoma has been difficult to evaluate because of the small numbers of cases seen, but it seemed that although treatment of the primary tumor in alveolar soft part sarcoma often is successful, treatment of metastatic tumors is unsuccessful.
  • A review of outcome after treatment of primary and metastatic disease in the 15 patients in our database with alveolar soft part sarcoma was done in order to evaluate this issue.
  • Nine of 15 patients presented with metastatic disease and one further patient developed metastases.
  • Adjuvant chemotherapy was administered to one patient with localized disease and to six patients with metastatic disease.
  • Treatment of metastatic tumors involved chemotherapy in seven patients, metastectomy in three patients, and radiation in two patients.
  • All instances of the metastatic disease either recurred or progressed.
  • Overall survival was 75% at 5 years and 40% at 10 years with a mean survival of 6.5 years, despite the high number of patients with metastatic disease.
  • Current treatment results in good local control of primary tumors, but poor control of metastatic tumors.
  • New approaches to treatment of metastatic alveolar soft part sarcoma must be investigated and applied.
  • [MeSH-major] Neoplasm Metastasis / pathology. Sarcoma, Alveolar Soft Part / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131883.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


86. Huang W, Zhang X, Li D, Chen J, Meng K, Wang Y, Lu Z, Zhou X: Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts. Virchows Arch; 2006 Feb;448(2):200-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts.
  • Clear cell sarcoma is a high-grade sarcoma with morphological features resembling those of malignant melanoma.
  • An osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts is very rare.
  • Herein, we report an unusual stomach tumor with microscopic and immunohistochemical characteristics of an osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts.
  • The differential diagnosis included gastrointestinal stromal tumor, primary or metastatic melanoma, and epithelioid malignant peripheral nerve sheath tumor.
  • To the best of our knowledge, this is possibly the second description of an osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Osteoclasts / pathology. Sarcoma, Clear Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Diagnosis, Differential. Giant Cells / chemistry. Giant Cells / pathology. Humans. Immunohistochemistry. Male. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220298.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / S100 Proteins
  •  go-up   go-down


87. Modritz D, Ladenstein R, Pötschger U, Amman G, Dieckmann K, Horcher E, Urban C, Meister B, Schmitt K, Jones R, Kaulfersch W, Haas H, Moser R, Stöllinger O, Peham M, Gadner H, Koscielniak E, Treuner J: Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr; 2005 Mar;117(5-6):196-209
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study.
  • OBJECTIVE: The aim of the CWS 96 Study was to achieve an optimal treatment in children and adolescents with soft tissue sarcoma (STS) implementing a further refinement of risk-adapted allocation to chemotherapy, surgery and radiotherapy.
  • METHODS: Treatment stratification was based on tumour histology, TNM status, postsurgical stage, localisation and age.
  • 59/89 patients had localised RMS-like (rhabdomayosarcoma) STS (EFS 73% +/- 7%), 14 had localised NON-RMS STS (EFS 54% +/- 16%) and 15 patients had metastatic disease at diagnosis (EFS 33% +/- 12%), 1 patient had fibromatosis.
  • [MeSH-major] Risk Assessment / methods. Sarcoma / mortality. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Austria / epidemiology. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Wien Klin Wochenschr. 2005 Mar;117(5-6):176-9 [15875755.001]
  • (PMID = 15875759.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


88. Bedre G, Gupta T, Rajasekharan P, Munshi A, Jalali R: Cerebellar, pancreatic, and paraspinal metastases in soft tissue sarcomas: unusual sites or changing patterns? JOP; 2007;8(4):444-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar, pancreatic, and paraspinal metastases in soft tissue sarcomas: unusual sites or changing patterns?
  • CONTEXT: Soft tissue sarcomas generally first metastasize to the lungs followed by the involvement of other sites such as lymph nodes and bones as part of the disseminated disease.
  • Cerebellar and pancreatic metastases from tumors of mesenchymal origin such as soft tissue sarcomas are exceptional, more so in the absence of pulmonary metastases.
  • CASE REPORT: A previously treated case of chest wall sarcoma presented with the sudden onset of neurological symptoms.
  • A metastasectomy of the solitary brain lesion confirmed a deposit from a previously treated sarcoma.
  • FDG-PET and CT scans revealed a large pancreatic and left paraspinal mass with intense tracer uptake suggestive of metastatic involvement.
  • A CT-guided biopsy was suggestive of high-grade sarcoma.
  • CONCLUSION: Cerebellar, pancreatic, and paraspinal metastases from soft tissue sarcomas are rare, especially in the absence of pulmonary metastases.
  • [MeSH-major] Cerebellar Neoplasms / secondary. Pancreatic Neoplasms / secondary. Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625297.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


89. Riggi N, Stamenkovic I: The Biology of Ewing sarcoma. Cancer Lett; 2007 Aug 28;254(1):1-10
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Biology of Ewing sarcoma.
  • They constitute some of the most aggressive adult and childhood cancers in that they have a high metastatic proclivity and are typically refractory to conventional chemo- and radiation therapy.
  • Ewing's sarcoma is a member of Ewing's family tumors (ESFT) and the second most common solid bone and soft tissue malignancy of children and young adults.
  • This review will highlight some of the most recent discoveries in the field of Ewing sarcoma biology and origins.
  • [MeSH-major] Sarcoma, Ewing / genetics. Sarcoma, Ewing / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetics Home Reference. consumer health - chromosome 11.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17250957.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS
  • [Number-of-references] 74
  •  go-up   go-down


90. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S: Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res; 2009 Feb 1;15(3):1096-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to sunitinib malate in advanced alveolar soft part sarcoma.
  • PURPOSE: Alveolar soft part sarcoma (ASPS) is a rare, chemoresistant soft tissue sarcoma.
  • EXPERIMENTAL DESIGN: Since July 2007, five patients with progressive metastatic ASPS have been treated with continuous SM 37.5 mg/d on a named basis.
  • [MeSH-major] Indoles / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrroles / therapeutic use. Sarcoma, Alveolar Soft Part / drug therapy
  • [MeSH-minor] Adult. Drug Evaluation. Female. Humans. Male. Middle Aged. Phosphorylation. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Signal Transduction / drug effects. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188185.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / sunitinib; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


91. Ferrari A, Brecht IB, Koscielniak E, Casanova M, Scagnellato A, Bisogno G, Alaggio R, Cecchetto G, Catania S, Meazza C, Int-Veen C, Kirsch S, Dantonello T, Carli M, Treuner J: The role of adjuvant chemotherapy in children and adolescents with surgically resected, high-risk adult-type soft tissue sarcomas. Pediatr Blood Cancer; 2005 Aug;45(2):128-34
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of adjuvant chemotherapy in children and adolescents with surgically resected, high-risk adult-type soft tissue sarcomas.
  • PURPOSE: This analysis evaluates whether adjuvant chemotherapy can be recommended for high-risk, surgically-resected, adult-type non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) within the new European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) protocol.
  • (1) despite the globally good prognosis of grossly-resected cases, patients with G3 and large-size have a high-risk of metastatic spread, and (2) MFS appears to be better in patients who had chemotherapy.
  • Based in part on these results, and in accordance with recent suggestions coming from the literature on adult sarcomas, the EpSSG NRSTS protocol will recommend adjuvant chemotherapy in high-risk surgically-resected patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852434.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, DeJager R, Anderson S: Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer; 2006 Dec 15;107(12):2881-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
  • In addition, Phase I clinical investigations suggested activity in STS (soft-tissue sarcoma).
  • METHODS: Eligible patients were those who had histologic evidence of locally advanced or metastatic STS and who had received 1 prior treatment regimen with an anthracycline-based chemotherapy for metastatic disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Oligopeptides / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Constipation / chemically induced. Fatigue / chemically induced. Female. Humans. Injections, Intravenous. Male. Middle Aged. Neutropenia / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17109446.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Oligopeptides; DQC51A0WQH / soblidotin
  •  go-up   go-down


93. Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P, Kapoor N, Molina A, Al-Kadhimi Z, Frankel P, Somlo G: Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res; 2009 Aug;29(8):3281-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
  • BACKGROUND: Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options.
  • CONCLUSION: Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Feasibility Studies. Female. Humans. Ifosfamide / administration & dosage. Immunoenzyme Techniques. Male. Melphalan / administration & dosage. Mesna / administration & dosage. Neoplasm Staging. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Neuroectodermal Tumors, Primitive, Peripheral / therapy. Osteosarcoma / pathology. Osteosarcoma / therapy. Prognosis. Prospective Studies. Protective Agents / administration & dosage. Remission Induction. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Safety. Sarcoma, Ewing / pathology. Sarcoma, Ewing / therapy. Survival Rate. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661346.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protective Agents; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


94. García Franco CE, Algarra SM, Ezcurra AT, Guillén-Grima F, San-Julián M, Mindán JP, Buxalleu WT: Long-term results after resection for soft tissue sarcoma pulmonary metastases. Interact Cardiovasc Thorac Surg; 2009 Aug;9(2):223-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results after resection for soft tissue sarcoma pulmonary metastases.
  • Isolated pulmonary metastases from soft tissue sarcomas (STS) occur in approximately 20% of the cases.
  • DFI, number of lung nodules at surgery and metastatic histology are significant prognostic factors for patients with resected pulmonary metastases from STS.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy. Sarcoma / secondary. Sarcoma / surgery. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454417.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Brecht IB, Ferrari A, Int-Veen C, Schuck A, Mattke AC, Casanova M, Bisogno G, Carli M, Koscielniak E, Treuner J: Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: discussion on the role of adjuvant therapies. Pediatr Blood Cancer; 2006 Jan;46(1):11-7
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: discussion on the role of adjuvant therapies.
  • Differently from adult oncologists that considered synovial sarcoma (SS) a tumor with uncertain chemosensitiveness, since two decades pediatric oncologists in Europe assumed that chemotherapy played an important role in SS treatment, so most pediatric patients were included in rhabdomyosarcoma protocols, receiving adjuvant chemotherapy regardless of risk factors.
  • No metastatic relapses occurred in Group I < or = 5 cm patients, while the outcome was poor for T2B patients (EFS 41%) due to a high rate of metastatic relapse.
  • [MeSH-major] Chemotherapy, Adjuvant. Radiotherapy, Adjuvant. Sarcoma, Synovial / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Germany / epidemiology. Humans. Infant. Italy / epidemiology. Male. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292743.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


96. Italiano A, Delva F, Mathoulin-Pelissier S, Le Cesne A, Bonvalot S, Terrier P, Trassard M, Michels JJ, Blay JY, Coindre JM, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol; 2010 Dec;21(12):2436-41
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database.
  • BACKGROUND: The predictive value of grade for benefit from adjuvant chemotherapy (AC) in soft tissue sarcoma (STS) patients has never been explored.
  • PATIENTS AND METHODS: From 1980 to 1999, 1513 adult patients with non-metastatic STS were included prospectively in the French Sarcoma Group database.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439343.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


97. Coindre JM: Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med; 2006 Oct;130(10):1448-53
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of soft tissue sarcomas: review and update.
  • CONTEXT: Histologic grading is the most important prognostic factor and the best indicator of metastatic risk in adult soft tissue sarcomas.
  • However, grading is useful in more than 90% of adult soft tissue sarcomas and has been adapted to pediatric nonrhabdomyosarcomatous sarcomas.
  • OBJECTIVE: To review the current value and limitations of histologic grading in soft tissue sarcomas.
  • DATA SOURCES: The reviews on grading and original studies on prognostic factors in soft tissue sarcomas were analyzed.
  • CONCLUSIONS: Grading is the best predictor of metastasis outcome in adult soft tissue sarcomas and should be part of the pathologic report.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090186.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


98. Picciotto F, Zaccagna A, Derosa G, Pisacane A, Puiatti P, Colombo E, Dardano F, Ottinetti A: Clear cell sarcoma (malignant melanoma of soft parts) and sentinel lymph node biopsy. Eur J Dermatol; 2005 Jan-Feb;15(1):46-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma (malignant melanoma of soft parts) and sentinel lymph node biopsy.
  • Clear cell sarcoma of the tendons and aponeuroses is an aggressive, rare soft tissue tumour that occurs predominantly in the extremities of young adults.
  • Although it appears to be histogenetically related to melanoma, its clinical behaviour resembles soft tissue sarcoma.
  • We describe a case of clear cell sarcoma of the hand and evaluate the feasibility of the sentinel lymph node biopsy (SLNB) technique in this kind of tumour.
  • Up to now, there are no reports that describe the use of SLNB in clear cell sarcoma.
  • Histological examination of the lymphnode allowed identification of metastatic cells and thus provide for radical lymphadenectomy.
  • [MeSH-major] Hand. Sarcoma, Clear Cell / pathology. Sentinel Lymph Node Biopsy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701594.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


99. Puhaindran ME, Steensma MR, Athanasian EA: Partial hand preservation for large soft tissue sarcomas of the hand. J Hand Surg Am; 2010 Feb;35(2):291-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial hand preservation for large soft tissue sarcomas of the hand.
  • In patients with large soft tissue sarcomas of the hand, partial hand preservation is extremely challenging for surgeons attempting a complete resection of the tumor with negative resection margins.
  • We conducted this review to examine the oncologic outcome, including local recurrence rate and patient overall survival, and functional outcome after resections for large soft tissue sarcomas with partial hand preservation.
  • METHODS: We performed a retrospective review of all patients with soft tissue sarcomas of the hand treated at our institution from 1995 to 2007.
  • Two patients had myxofibrosarcoma, 2 patients had synovial sarcoma, 2 patients had malignant fibrous histiocytoma, 1 patient had a malignant peripheral nerve sheath tumor, and 1 patient had a liposarcoma.
  • Two patients had American Joint Committee on Cancer stage 1b tumors, and 6 patients had American Joint Committee on Cancer stage 3 tumors.
  • RESULTS: Of the 8 patients, 1 died of distant metastatic disease, 1 developed local tumor recurrence and is alive with locally recurrent disease, and the other 6 patients are completely disease-free.
  • CONCLUSIONS: Partial hand preservation is possible in selected patients with large soft tissue sarcomas of the hand, obtaining low local recurrence rates, good overall survival, and good functional outcome.
  • [MeSH-major] Hand / surgery. Limb Salvage / methods. Neoplasm Recurrence, Local / pathology. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / methods. Arm. Artificial Limbs. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prosthesis Fitting. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20141899.001).
  • [ISSN] 1531-6564
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, Carr RA, Gordon GB, Demetri GD: Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol; 2008 Dec 1;26(34):5583-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
  • Phase I study results for ABT-510, which inhibits angiogenesis via a novel thrombospondin-mimetic mechanism, suggested activity in soft tissue sarcoma (STS) patients.
  • PATIENTS AND METHODS: Patients with metastatic or unresectable STS were randomly assigned to treatment with one of two ABT-510 dose schedules (20 mg once a day [20 mg], n = 42; or 100 mg twice a day [200 mg], n = 46), which were self-administered subcutaneously in 28-day treatment periods.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Oligopeptides / pharmacokinetics. Oligopeptides / pharmacology. Sarcoma / drug therapy. Thrombospondin 1 / metabolism
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neovascularization, Pathologic. Odds Ratio. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt; 0 / Oligopeptides; 0 / Thrombospondin 1
  •  go-up   go-down






Advertisement